Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304236 | 1.00 | HRH4 (0.56) | HRH4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6306591 | 0.90 | HRH4 (0.60) | HRH4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL23110691 | 0.84 | KMT2A (0.56) | HRH4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4928239 | 0.84 | ALDH1A1 (0.59) | HRH4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4928778 | 0.84 | NQO2 (0.50) | HRH4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1138259 | 0.82 | HRH4 (0.54) | HRH4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4925400 | 0.82 | HRH4 (0.54) | HRH4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL444482 | 0.82 | KDM4E (0.44) | HRH4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2178510 | 0.80 | TDP1 (0.58) | HRH4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL28408048 | 0.80 | HRH4 (0.51) | HRH4MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598173-B2 | 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-12-03 | — | — | US | disclosed |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8314100-B2 | 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-01-21 | — | — | US | disclosed |
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-01-21 | — | — | US | disclosed |
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-01-21 | — | — | US | disclosed |
| EP-2044027-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-04-08 | — | — | EP | disclosed |
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008003702-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003702-A2 | FUSED BICYCLIC COMPOUNDS INTERACTING WITH THE HISTAMINE H4 RECEPTOR | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2008-01-10 | — | — | WO | disclosed |
| EP-1819698-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | Rexahn Pharmaceuticals, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006054830-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-6927214-B1 | Non-peptide GLP-1 agonists | NOVO NORDISK A/S (DK) | 2005-08-09 | — | — | US | disclosed |
| EP-1147094-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042026-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-20 | — | — | WO | disclosed |
| US-4623725-A | [1,2,4]Triazolo[4,3-a]quinoxaline-4-amine derivatives | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0107455-B1 | TRIAZOLOQUINOXALINES AS ANTIDEPRESSANTS AND ANTIFATIGUE AGENTS | PFIZER INC. (US) | 1986-07-09 | — | — | EP | disclosed |
| US-4547501-A | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | PFIZER INC. (US) | 1985-10-15 | — | — | US | disclosed |
| US-4495187-A | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | PFIZER INC. (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0107455-A1 | Triazoloquinoxalines as antidepressants and antifatigue agents | PFIZER INC. (US) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | HRAS, CDK4, KRAS | HRH4 984/4885MEN1 2176/4885KMT2A 549/4885 |
| US-20100016293-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | HRH4, HRH3, HRH2 | HRH4 1/4885MEN1 2001/4885KMT2A 1494/4885 |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | HRAS, CDK4, KRAS | HRH4 846/4885MEN1 2727/4885KMT2A 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.